150 related articles for article (PubMed ID: 37890416)
21. Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype.
Dessources K; Ferrando L; Zhou QC; Iasonos A; Abu-Rustum NR; Reis-Filho JS; Riaz N; Zamarin D; Weigelt B
Gynecol Oncol; 2023 Apr; 171():15-22. PubMed ID: 36804617
[TBL] [Abstract][Full Text] [Related]
22. Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies The Cancer Genome Atlas-like Prognostic Subgroups.
Irshaid L; Costigan DC; Dong F; Matulonis UA; Nucci MR; Kolin DL
Mod Pathol; 2023 May; 36(5):100123. PubMed ID: 36857998
[TBL] [Abstract][Full Text] [Related]
23. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
24. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Landa I; Ganly I; Chan TA; Mitsutake N; Matsuse M; Ibrahimpasic T; Ghossein RA; Fagin JA
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1562-6. PubMed ID: 23833040
[TBL] [Abstract][Full Text] [Related]
25. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
[TBL] [Abstract][Full Text] [Related]
26. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
27. TERT promoter mutations in primary and secondary glioblastomas.
Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.
Isharwal S; Audenet F; Drill E; Pietzak EJ; Iyer G; Ostrovnaya I; Cha E; Donahue T; Arcila M; Jayakumaran G; Berger MF; Rosenberg JE; Bajorin DF; Coleman J; Dalbagni G; Reuter VE; Bochner BH; Solit DB; Al-Ahmadie HA
Eur Urol Focus; 2019 Mar; 5(2):201-204. PubMed ID: 28802642
[TBL] [Abstract][Full Text] [Related]
29. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.
Remke M; Ramaswamy V; Peacock J; Shih DJ; Koelsche C; Northcott PA; Hill N; Cavalli FM; Kool M; Wang X; Mack SC; Barszczyk M; Morrissy AS; Wu X; Agnihotri S; Luu B; Jones DT; Garzia L; Dubuc AM; Zhukova N; Vanner R; Kros JM; French PJ; Van Meir EG; Vibhakar R; Zitterbart K; Chan JA; Bognár L; Klekner A; Lach B; Jung S; Saad AG; Liau LM; Albrecht S; Zollo M; Cooper MK; Thompson RC; Delattre OO; Bourdeaut F; Doz FF; Garami M; Hauser P; Carlotti CG; Van Meter TE; Massimi L; Fults D; Pomeroy SL; Kumabe T; Ra YS; Leonard JR; Elbabaa SK; Mora J; Rubin JB; Cho YJ; McLendon RE; Bigner DD; Eberhart CG; Fouladi M; Wechsler-Reya RJ; Faria CC; Croul SE; Huang A; Bouffet E; Hawkins CE; Dirks PB; Weiss WA; Schüller U; Pollack IF; Rutkowski S; Meyronet D; Jouvet A; Fèvre-Montange M; Jabado N; Perek-Polnik M; Grajkowska WA; Kim SK; Rutka JT; Malkin D; Tabori U; Pfister SM; Korshunov A; von Deimling A; Taylor MD
Acta Neuropathol; 2013 Dec; 126(6):917-29. PubMed ID: 24174164
[TBL] [Abstract][Full Text] [Related]
30. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
Thielmann CM; Matull J; Zaremba A; Murali R; Chorti E; Lodde G; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Kretz J; Möller I; Sucker A; Paschen A; Livingstone E; Zimmer L; Hadaschik E; Ugurel S; Schadendorf D; Griewank KG
Eur J Cancer; 2022 Jan; 161():99-107. PubMed ID: 34936949
[TBL] [Abstract][Full Text] [Related]
31. Interpretation of somatic POLE mutations in endometrial carcinoma.
León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
[TBL] [Abstract][Full Text] [Related]
32. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.
Vazquez Vde L; Vicente AL; Carloni A; Berardinelli G; Soares P; Scapulatempo C; Martinho O; Reis RM
Melanoma Res; 2016 Apr; 26(2):93-9. PubMed ID: 26709572
[TBL] [Abstract][Full Text] [Related]
33. Germline
de Jonge MM; Ritterhouse LL; de Kroon CD; Vreeswijk MPG; Segal JP; Puranik R; Hollema H; Rookus MA; van Asperen CJ; van Leeuwen FE; Smit VTHBM; Howitt BE; Bosse T;
Clin Cancer Res; 2019 Dec; 25(24):7517-7526. PubMed ID: 31492746
[TBL] [Abstract][Full Text] [Related]
34. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
[TBL] [Abstract][Full Text] [Related]
35. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death.
Jamieson A; Huvila J; Chiu D; Thompson EF; Scott S; Salvador S; Vicus D; Helpman L; Gotlieb W; Kean S; Samouelian V; Köbel M; Kinloch M; Parra-Harran C; Offman S; Grondin K; Irving J; Lum A; Senz J; Leung S; McConechy MK; Plante M; Kommoss S; Huntsman DG; Talhouk A; Gilks CB; McAlpine JN
Mod Pathol; 2023 Apr; 36(4):100085. PubMed ID: 36788084
[TBL] [Abstract][Full Text] [Related]
36. Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy.
Neron M; Guille A; Allegre L; Colombo PE; Leaha C; Adelaide J; Carbuccia N; Courtier F; Boissiere F; Crapez E; Fabbro M; Gouy S; Mamessier E; Lambaudie É; Birnbaum D; Bertucci F; Chaffanet M
J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629078
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive analysis of germline drivers in endometrial cancer.
Gordhandas S; Rios-Doria E; Cadoo KA; Catchings A; Maio A; Kemel Y; Sheehan M; Ranganathan M; Green D; Aryamvally A; Arnold AG; Salo-Mullen E; Manning-Geist B; Sia T; Selenica P; Da Cruz Paula A; Vanderbilt C; Misyura M; Leitao MM; Mueller JJ; Makker V; Rubinstein M; Friedman CF; Zhou Q; Iasonos A; Latham A; Carlo MI; Murciano-Goroff YR; Will M; Walsh MF; Issa Bhaloo S; Ellenson LH; Ceyhan-Birsoy O; Berger MF; Robson ME; Abu-Rustum N; Aghajanian C; Offit K; Stadler Z; Weigelt B; Mandelker DL; Liu YL
J Natl Cancer Inst; 2023 May; 115(5):560-569. PubMed ID: 36744932
[TBL] [Abstract][Full Text] [Related]
38. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y
PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608
[TBL] [Abstract][Full Text] [Related]
39. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
Spiegl-Kreinecker S; Lötsch D; Neumayer K; Kastler L; Gojo J; Pirker C; Pichler J; Weis S; Kumar R; Webersinke G; Gruber A; Berger W
Neuro Oncol; 2018 Nov; 20(12):1584-1593. PubMed ID: 30010853
[TBL] [Abstract][Full Text] [Related]
40. TERT promoter mutations in penile squamous cell carcinoma: high frequency in non-HPV-related type and association with favorable clinicopathologic features.
Kim SK; Kim JH; Han JH; Cho NH; Kim SJ; Kim SI; Choo SH; Kim JS; Park B; Kwon JE
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1125-1135. PubMed ID: 33635430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
